Novocure (NSDQ:NVCR) touted health-related quality of life analyses from a pivotal Phase III trial combining its Optune device with standard temozolomide chemotherapy for patients with newly diagnosed glioblastoma. The data showed that adding Optune to temozolomide did not negatively impact health-related quality of life, except for itchy skin which the company attributed to skin irritation […]
One Drop, MannKind ink partnership for connected, inhaled diabetes tech
MannKind Corp. (NSDQ:MNKD) and One Drop said today that the companies agreed to ink a collaborative deal to add MannKind’s Afrezza inhaled insulin to One Drop’s digital diabetes management platform. The group plans to evaluate access and cost saving initiatives, customized patient coaching and innovative packaging for a reusable Afrezza inhaler integrated with Bluetooth tech. […]
Study: Nanoparticle shrinks tumor size by 80% in mouse model
Researchers from the Mayo Clinic have developed a type of cancer-fighting nanoparticle that is designed to shrink breast cancer tumors and prevent recurrence. In a mouse model, the therapy yielded a 70-80% reduction in tumor size and mice treated with the nanoparticles demonstrated resistance to future tumor recurrence a month later. The nanoparticle is coated […]
Regeneron posts mixed Q1 results, Eylea growth slows
Shares in Regeneron (NSDQ:REGN) rose today after the company beat revenue expectations on The Street with its 1st quarter financial results. The company’s total sales rose to $1.32 billion, exceeding analysts’ estimate of $1.30 billion. Regeneron’s bottom line jumped 37% to $248.9 million. Adjusted to exclude 1-time items, earnings per share were $2.92, which missed analysts’ […]
Cerus shares fall after Q1 miss
Shares in Cerus Corp. (NSDQ:CERS) fell -18% today after the company missed expectations on Wall Street with its 1st quarter results. The Concord, Calif.-based company posted a net loss of -$18.7 million, or -18¢ per share, on sales of $7 million for the 3 months ended March 31, for bottom-line loss of -10.7% on sales growth of […]
Anika misses Q1 earnings by a penny
Shares in Anika Therapeutics (NSDQ:ANIK) fell today after the orthopedics company missed expectations on Wall Street with its 1st quarter results. The Bedford, Mass.-based company posted profits of $5.5 million, or 37¢ per share, on sales of $23.4 million for the 3 months ended March 31, for bottom-line loss of -20.3% on sales growth of 4.9% compared […]
Glaukos shares tumble despite Q1 beat
Shares in Glaukos (NYSE:GKOS) fell -10% today after the ophthalmic medtech company beat expectations on Wall Street with its 1st quarter results. The San Clemente, Calif.-based company posted profits of $878,000, or 2¢ per share, on sales of $35.9 million for the 3 months ended March 31, for bottom-line loss of -2% on sales growth of […]
Novo Nordisk launches Xultophy diabetes therapy in U.S.
Novo Nordisk (NYSE:NVO) said today that it launched its Type II diabetes combination therapy, Xultophy, in pharmacies across the U.S. The injection is a combination of insulin degludec and liraglutide that is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes. In clinical trials, Xultophy reduced […]
Pieris, AstraZeneca ink $45m deal for inhaled respiratory drugs
Pieris Pharmaceuticals (NSDQ:PIRS) inked a $45 million deal with AstraZeneca (NYSE:AZN) to develop a group of inhaled drugs for respiratory diseases. According to the deal, Pieris will get $45 million up front to bring an experimental asthma drug into human clinical trials. The drug is slated to begin Phase I testing this year, which will […]
Nordisk shares climb after Q1 beat
Shares in Novo Nordisk (NYSE:NVO) rose today after the insulin-maker met expectations on Wall Street with its 1st quarter results. The Denmark-based company posted profits of $1.49 billion, or 60¢ per share, on sales of $4.18 billion for the 3 months ended March 31, for bottom-line growth of 7% on sales growth of 5% compared with […]